Clinical trial
The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)
NCT01732718 is registered in ClinicalTrials.gov with University of North Carolina, Chapel Hill as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (in the Grant Entitled: Endothelial Dysfunction in the Pathogenesis of Sickle Cell Nephropathy)
- Lead sponsor
- University of North Carolina, Chapel Hill
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2013
- Completion date
- January 9, 2018
- Enrollment
- 13 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
sickle cell disease, sickle cell nephropathy